Labcorp Rolls Out First FDA-Cleared Blood Test for Alzheimer's in Primary Care
Event summary
- Labcorp launched the Elecsys® pTau-181 blood test nationwide on February 11, 2026, the first FDA-cleared test for Alzheimer's assessment in primary care.
- The test, developed by Roche Diagnostics and FDA-cleared in 2025, helps rule out Alzheimer's by identifying patients unlikely to have amyloid pathology.
- Labcorp's test offers a 97.9% negative predictive value and is performed via a simple blood draw, reducing the need for costly or invasive brain scans.
- The test is available for patients aged 55 and older experiencing cognitive decline, expanding Labcorp's portfolio of Alzheimer's disease blood tests.
The big picture
Labcorp's launch addresses a critical gap in early Alzheimer's diagnosis, enabling primary care physicians to streamline patient evaluations amid a national shortage of neurologists. The test's high negative predictive value and non-invasive nature could set a new standard for cognitive decline assessments, potentially reshaping the diagnostic landscape for neurodegenerative diseases. With an estimated 7.2 million Americans living with Alzheimer's, the test's availability could significantly impact patient outcomes and healthcare resource allocation.
What we're watching
- Market Adoption
- How quickly primary care clinicians will integrate the Elecsys® pTau-181 test into standard diagnostic protocols.
- Competitive Response
- Whether competitors will accelerate development of similar blood-based diagnostic tools for Alzheimer's.
- Regulatory Impact
- The pace at which additional Alzheimer's diagnostic tools gain FDA clearance, expanding the primary care toolkit.
Related topics